Introduction
============

*Aeromonas* species, belonging to the genus *Aeromonas*, are oxidase-producing Gram-negative rods that can grow on MacConkey agar and ferment carbohydrates\[[@B1]\]. These aquatic microorganisms have been associated with a variety of human diseases \[[@B1]\]. *Aeromonas* species are proliferative and omnipresent in both fresh water and soils \[[@B2]\], and are occasionally isolated from the feces of healthy people \[[@B3]\]. Among 14 known species identified in the genus *Aeromonas*, many, although not all, are considered to be pathogenic \[[@B4]\]. More than 85% of *Aeromonas*-implicated clinical diseases are caused by the *Aeromonas hydrophila*, *Aeromonas caviae*, and *Aeromonas veronii* biovar *sobria* \[[@B2]\]. These infections are acquired in both community and hospital settings, and both immunocompetent and immunocompromised patients are susceptible. *Aeromonas* species can cause invasive and fatal infections in immunocompromised hosts and have been recognized as a serious threat to human beings \[[@B4]\].

The *Aeromonas* infection-related disease spectrum in humans has expanded; it now includes acute gastroenteritis, bacteremia, pancreatitis, hepatobiliary-tract infections, soft-tissue infections, indwelling-device-related infections, brain abscesses, meningitis, endocarditis, pleuropulmonary infections, peritonitis, and hemolytic-uremic syndrome \[[@B1][@B2][@B3][@B4][@B5][@B6][@B7][@B8]\]. The most common underlying conditions known to be associated with *Aeromonas* bacteremia are malignancy and hepatobiliary diseases \[[@B5]\]. *Aeromonas* spp. tend to produce at least three ß-lactamases, namely a penicillinase, cephalosporinase, and carbapenemase, which are all chromosome-encoded \[[@B6]\]. Nevertheless, to date, antibiotic resistance has not been a major problem for strains isolated from the environment. In contrast, clinical studies of *Aeromonas* infections are relatively rare, and the relevant antibiotic susceptibility profile, accordingly, remains vague. Previous studies have attempted to identify risk factors; however, those studies considered only a few risk factors and resistance to a limited number of antimicrobials \[[@B2][@B7][@B8]\]. *Aeromonas* bacteremia in patients with cirrhosis or malignancy has been found to be associated with a higher mortality rate than bacteremia caused by other organisms \[[@B8]\]. The present study is the largest retrospective clinical investigation to analyze various data on monomicrobial *Aeromonas* bacteremia.

The objectives of this study were to elucidate the clinical characteristics of *Aeromonas* bacteremia and to scrutinize the antimicrobial susceptibility of *Aeromonas* to optimal therapy. We also aimed to identify risk factors for mortality in patients with *Aeromonas* bacteremia.

Material and Methods
====================

1. Patients {#sec1}
-----------

We retrospectively reviewed the medical records of patients who were diagnosed with *Aeromonas* bacteremia between January 2000 and December 2013 in multiple centers (Samsung Medical Center \[Seoul\], Dankook University Hospital \[Cheonan\], Dong-A University Hospital \[Busan\], and Jeju University Hospital \[Jeju\]). Patient records and information were anonymized and de-identified prior to analysis. Institutional review board approval was obtained for retrospective evaluation of the patients (DKUH 2015-01-014).

*Aeromonas* bacteremia was defined as the presence of an *Aeromonas*-positive blood culture, with concomitant signs and symptoms of infection. When the patient's blood culture yielded only one type of pathogen, monomicrobial bacteremia was diagnosed; when more than one type of pathogen was identified, the diagnosis of polymicrobial bacteremia was made. We included only patients with monomicrobial bacteremia in our analysis. Hospital-acquired infections were defined as bacteremic episodes detected at least 72 h after admission in patients who showed no clinical evidence of bacteremia on admission.

Information on age, sex, underlying disease, blood laboratory data, culture results, probable portals of entry, type of antimicrobial agents for treatment, type of medical procedure during treatment, and clinical outcome was collected for each of the patients. Illness severity and comorbidity at the patients' first presentation with bacteremia to the hospital were graded using the Pitt bacteremia score \[[@B5][@B9]\] and Charlson's weighted comorbidity index \[[@B5]\], respectively. Patients with *Aeromonas* bacteremia were surveyed for concomitant infection foci; those lacking such foci were classified as having primary bacteremia.

2. Antimicrobial susceptibility test {#sec2}
------------------------------------

*Aeromonas* isolates were obtained by processing of blood culture samples in a BACTEC Model 9240 (BD Diagnostic Instrument Systems, Sparks, MD, USA) or BacT/ALERT 3D (bioMerieux. Inc., Haselwood, MO, USA). *Aeromonas* was identified by means of a standard identification card. Antibiotic susceptibility testing of the isolates was carried out via an automated system at each hospital. Quality-control protocols and minimum inhibitory concentration breakpoints (MICs) were used in compliance with the standards established by the Clinical and Laboratory Standards Institute \[[@B8]\].

3. Statistical analysis {#sec3}
-----------------------

Statistical analyses were carried out in SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were expressed as the mean and standard deviation (SD) or median (range) according to their homogeneity. The categorical variables were compared using the Chi-Square test or Fishers exact test (when necessary). The quantitative variables were compared using the Student--Fisher *t* test or analysis of variance. The risk factors for infection-related mortality were evaluated by univariate and multivariate logistic regression analyses. Factors with a *P-*value of 0.2 in the univariate analysis, excepting those considered to be strongly associated with other variables, were entered into the multiple logistic regression analysis. A value of *P* \<0.05 was considered statistically significant.

Results
=======

1. Patient characteristics {#sec1___1}
--------------------------

Eight-hundred-and-twenty-four cases of *Aeromonas* bacteremia were enrolled, among which 488 cases of polymicrobial *Aeromonas* bacteremia were observed. The remaining 336 monomicrobial *Aeromonas* bacteremia cases were included in this study ([Table 1](#T1){ref-type="table"}). The major causes of bacteremia were hepatobiliary tract infections (50.6%), followed by peritonitis (18.5%) and primary bacteremia (17.9%). Community-acquired bacteremia was shown in 242 cases (72.0%). The infections usually occurred in patients with solid-organ malignancy (42.3%), hepatic cirrhosis (39.3%), diabetes mellitus (25.6%), or leukemia (7.1%). Concomitant anticancer chemotherapy had been administered in 74 patients (22.0%). The three leading clinical manifestations were fever (38.7%), septic shock (25.6%), and altered consciousness (17.9%). Initial usage of inappropriate antimicrobial agent was noticed in 140 cases. One-hundred-and-sixty-six cases showed antimicrobial-agent combination therapy. The median duration of treatment was 10 days. In 272 cases, antimicrobial-agent initiation within 6 h of symptom manifestations was observed. Fifty patients died of *Aeromonas* bacteremia.

###### Characteristics of enrolled patients
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  Characteristics                                                                                        Value (%)
  ------------------------------------------------------------------------------------------------------ ----------------
  Age (year, median)                                                                                     57
  Sex ratio (male/female)                                                                                2.36 (236/100)
  Community-acquired: Hospital-acquired                                                                  242:94
  Underlying diseases                                                                                    
   Solid organ malignancy                                                                                142 (42.3%)
   Hepatic cirrhosis                                                                                     132 (39.3%)
   Diabetes mellitus                                                                                     86 (25.6%)
   Leukemia                                                                                              24 (7.1%)
   Concomitant chemotherapy                                                                              74 (22.0%)
  Clinical manifestations                                                                                
   Fever (\>38℃)                                                                                         130 (38.7%)
   Hypothermia                                                                                           34 (10.1%)
   Shock                                                                                                 86 (25.6%)
   Altered consciousness                                                                                 60 (17.9%)
   Abdominal pain                                                                                        52 (15.5%)
   Dyspnea                                                                                               48 (14.3%)
  Site of infection                                                                                      
   Hepatobiliary infections                                                                              170 (50.6%)
   Peritonitis                                                                                           62 (18.5%)
   Primary bacteremia                                                                                    60 (17.9%)
   Pneumonia                                                                                             20 (5.9)
   Skin and soft-tissue infection                                                                        14 (4.2%)
   Catheter related infection                                                                            10 (3.0%)
  Usage of Antimicrobial agent                                                                           
   Initial Appropriate : Inappropriate                                                                   196:140
   Combination therapy                                                                                   166 (49.4%)
   Duration of treatment (days, median)                                                                  10
   Number of patients in which antimicrobial agents were initiated within 6 h of symptom manifestation   272 (81.0%)

2. Seasonal distribution of *Aeromonas* bacteremia {#sec2___1}
--------------------------------------------------

A trend toward more frequent occurrence during the warmer seasons (May to October; n = 232; 69.0%) was observed. Most of the community-acquired infections (176 of 242, 72.7%) occurred during these seasons ([Fig. 1](#F1){ref-type="fig"}).

![Monthly distribution of *Aeromonas* bacteremia](ic-48-274-g001){#F1}

3. Differences in clinical characteristics and antimicrobial susceptibility between species {#sec3___1}
-------------------------------------------------------------------------------------------

*A. hydrophila* was less frequently involved in primary bacteremia and was more frequent in skin and soft-tissue infections and peritonitis (*P* \<0.05) than in infections with other species ([Table 2](#T2){ref-type="table"}). *A. caviae* was less prevalent in skin and soft-tissue infections (*P* = 0.009) and more prevalent in primary bacteremia (*P* = 0.017) than in infections with other species. Spontaneous bacterial peritonitis (SBP) was more common with *A. hydrophila* infections (50/62 SBP cases). Pneumonia was more common with *Aeromonas salmonicida* infection (*P* \<0.001). Hospital-acquired infections were more common among patients with *A. caviae* and *A. salmonicida* infections (*P* \<0.001). Underlying diseases differed according to species: *A. veronii* and *A. sorbia* infections were more frequent in liver cirrhosis; *A. caviae* and *A. sorbia* infections were more frequent in patients with solid-organ cancers; *A. salmonicida* infections were more common in those with leukemia. Moreover, *A. caviae* infections occurred more frequently during concurrent chemotherapy (*P* = 0.004), and *A. hydrophila* tended to be present in cases of shock (*P* \<0.001). Liver function test results were worse in cases with *A. hydrophila* infection than in cases with infections involving other species (*P* = 0.001).

###### Clinical presentation, laboratory findings, and antimicrobial susceptibility in *Aeromonas hydrophila*, *Aeromonas caviae, Aeromonas sobria,* *Aeromonas veronii,* and *Aeromonas salmonicida* bacteremia
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  Variables                                                           *Aeromonas hydrophila* (n = 198)       *Aeromonas caviae* (n = 102)   *Aeromonas sobria* (n = 20)   *Aeromonas veronii* (n = 10)   *Aeromonas salmonicida* (n = 6)   *P*-value
  ------------------------------------------------------------------- -------------------------------------- ------------------------------ ----------------------------- ------------------------------ --------------------------------- --------------
  Age (mean)                                                          56.5                                   53.8                           54.25                         53.3                           69.3                              0.605
  Sex (Male:Female)                                                   126:72                                 82:20                          16:4                          8:2                            4:2                               **0.032**
  Pitt bacteremia score (mean)                                        1.98                                   1.12                           0.80                          2.60                           4.67                              **\< 0.001**
  Charlson weighted comorbidity index (mean)                          4.39                                   4.02                           6.40                          5.00                           2.00                              **\< 0.001**
  Hospital stay (day, mean)                                           35.90                                  19.45                          8.60                          12.20                          39.67                             **0.004**
  Hospital-acquired bacteremia                                        44 (22.2%)                             42 (41.2%)                     2 (10.0%)                     2 (20.0%)                      4 (66.7%)                         **\< 0.001**
  Mortality                                                           34 (17.2%)                             12 (11.8%)                     0 (0%)                        2 (20.0%)                      2 (33.3%)                         0.140
  Source of infection                                                                                                                                                                                                                      **\< 0.001**
   Hepatobiliary infections                                           90 (45.5%)                             62 (60.8%)                     10 (50.0%)                    6 (60.0%)                      2 (33.3%)                         0.116
   Peritonitis                                                        50 (25.3%)                             8 (7.8%)                       2 (10.0%)                     2 (20.0%)                      0 (0%)                            **0.003**
   Primary bacteremia                                                 30 (15.2%)                             22 (21.6%)                     8 (40.0%)                     0 (0%)                         0 (0%)                            **0.017**
   Pneumonia                                                          12 (6.1%)                              4 (3.9%)                       0 (0%)                        0 (0%)                         4 (66.7%)                         **\< 0.001**
   Skin and soft-tissue infections                                    12 (6.1%)                              0 (0%)                         0 (0%)                        2 (20.0%)                      0 (0%)                            **0.009**
  Underlying diseases                                                                                                                                                                                                                      
   Diabetes mellitus                                                  42 (21.2%)                             30 (29.4%)                     8 (40.0%)                     4 (40.0%)                      2 (33.3%)                         0.182
   Hepatic cirrhosis                                                  78 (39.4%)                             32 (31.4%)                     14 (70.0%)                    8 (80.0%)                      0 (0%)                            **\< 0.001**
   Solid organ malignancy                                             68 (34.3%)                             52 (51.0%)                     18 (90.0%)                    4 (40.0%)                      0 (0%)                            **\< 0.001**
   Cerebrovascular attack                                             4 (2.0%)                               2 (1.96%)                      0 (0%)                        2 (20.0%)                      2 (33.3%)                         **\< 0.001**
   Concurrent chemotherapy                                            34 (17.2%)                             28 (27.5%)                     10 (50.0%)                    2 (20.0%)                      0 (0%)                            **0.004**
  Central venous catheterization                                      56 (28.3%)                             20 (19.6%)                     0 (0%)                        0 (0%)                         4 (66.7%)                         **0.001**
  Urinary catheterization                                             62 (31.3%)                             16 (15.7%)                     0 (0%)                        0 (0%)                         4 (66.7%)                         **\< 0.001**
  Ventilator-assisted state                                           14 (7.1%)                              0 (0%)                         0 (0%)                        0 (0%)                         4 (66.7%)                         **\< 0.001**
  Shock                                                               66 (33.3%)                             14 (13.7%)                     0 (0%)                        4 (40.0%)                      2 (33.3%)                         **\< 0.001**
  Use combination of antimicrobial agents                             107 (54.0%)                            50 (49.0%)                     0 (0%)                        3 (30.0%)                      6 (100.0%)                        **\< 0.001**
  Inappropriate antimicrobial agent use                               72 (36.4%)                             60 (58.8%)                     8 (40.0%)                     0 (0%)                         0 (0%)                            0.065
  Duration of antimicrobial agent use (day, mean)                     11.23                                  12.69                          9.40                          8.40                           18.00                             **\< 0.001**
  Laboratory findings                                                                                                                                                                                                                      
   White blood cell count (number/ mm^3^)                             12.45                                  16.66                          4.83                          10.02                          17.02                             **\< 0.001**
   Platelet (×10^3^/mm^3^)                                            118.35                                 136.53                         59.10.                        72.40                          226.33                            **\< 0.001**
   Glucose (mg/dL)                                                    164.76                                 162.18                         132.70                        165.00                         292.00                            **\< 0.001**
   Alkaline phosphatase (ALP) (IU/L, mean)                            380.95                                 217.63                         159.00                        153.00                         499.33                            **\< 0.001**
   Aspartate transaminase (AST) (U/L, mean)                           209.30                                 286.27                         56.50                         596.00                         140.67                            **\< 0.001**
   Alanine transaminase (ALT) (U/L, mean)                             140.33                                 184.31                         42.90                         344.00                         72.00                             **\< 0.001**
   Bilirubin (mg/dL)                                                  6.62                                   6.20                           2.78                          7.71                           0.60                              **\< 0.001**
   Prothrombin time (PT) (INR, mean)                                  2.01                                   1.98                           1.60                          1.73                           1.18                              **\< 0.001**
   activated partial thromboplastin time (aPTT) (sec)                 55.29                                  47.97                          45.76                         47.14                          29.03                             **\< 0.001**
   Creatinine (mg/dL)                                                 1.27                                   1.20                           0.93                          1.12                           1.03                              **\< 0.001**
  Antimicrobial agent (susceptibility within all isolates, n \[%\])   Susceptibility within species, n (%)                                                                                                                                 
   Ampicillin (28 \[8.3%\])                                           8 (4.0%)                               16 (15.7%)                     4 (20%)                       0 (0%)                         0 (0%)                            **\<0.001**
   Ampicillin/Sulbactam (92 \[28.9%\])                                50 (25.3%)                             32 (31.4%)                     10 (50%)                      0 (0%)                         0 (0%)                            **0.014**
   Piperacillin (268 \[79.8%\])                                       154 (77.8%)                            82 (80.4%)                     20 (100%)                     10 (100%)                      2 (33.3%)                         **0.003**
   Piperacillin/Tazobactam (284 \[84.5%\])                            160 (80.8%)                            92 (90.2%)                     20 (100%)                     10 (100%)                      2 (33.3%)                         **\<0.001**
   Ceftriaxone (284 \[84.5%\])                                        170 (85.9%)                            84 (82.4%)                     20 (100%)                     8 (80%)                        2 (33.3%)                         **0.002**
   Ceftazidime (312 \[92.9%\])                                        182 (91.9%)                            98 (96.1%)                     20 (100%)                     10 (100%)                      2 (33.3%)                         **\<0.001**
   Ciprofloxacin (302 \[89.9%\])                                      176 (89.9%)                            90 (88.2%)                     20 (100%)                     10 (100%)                      6 (100%)                          0.334
   Imipenem (303 \[90.2%\])                                           165 (83.3%)                            102 (100%)                     20 (100%)                     10 (100%)                      6 (100%)                          **0.021**
   Tobramycin (288 \[85.7%\])                                         160 (80.8%)                            100 (98.0%)                    14 (70%)                      8 (80%)                        6 (100%)                          **\<0.001**
   Gentamicin (312 \[92.9%\])                                         178 (89.9%)                            100 (98.0%)                    20 (100%)                     8 (80%)                        6 (100%)                          **0.024**
   Amikacin (326 \[97.0%\])                                           188 (94.9%)                            102 (100%)                     20 (100%)                     10 (100%)                      6(100%)                           0.127
   Trimethoprim/Sulfamethoxazole (294 \[87.8%\])                      167 (84.3%)                            97 (95.1%)                     20 (100%)                     8 (80%)                        2 (33.3%)                         **\<0.001**

*A. hydrophila* accounted for 58.9% of cases; there were 102 cases of *A. caviae* (30.4%), 20 cases of *A. sobria* (6.0%), 10 cases of *A. veronii* (3.0%), and six cases of *A. salmonicida* (1.7%) infections ([Table 2](#T2){ref-type="table"}).

All 336 isolates were included in the analysis of antimicrobial susceptibility. More than 90% of cases were susceptible only to ceftazidime, ciprofloxacin, imipenem, gentamicin, and amikacin. Among the five distinct *Aeromonas* complexes identified, *A. hydrophila* was more often resistant to antimicrobial agents. The exceptions were the *Aeromonas* isolates from Jeju University Hospital: these 20 (100%) cases were susceptible to piperacillin, piperacillin/tazobactam, ceftriaxone, ceftazidime, imipenem, ciprofloxacin, tobramycin, gentamicin, and amikacin.

4. Comparison of community-acquired and hospital-acquired *Aeromonas* bacteremia {#sec4}
--------------------------------------------------------------------------------

No clustered cases of hospital-acquired *Aeromonas* bacteremia were noted. Individual cases developed within 4--42 days (median: 10 days) after admission. Community-acquired *Aeromonas* bacteremia differed from hospital-acquired bacteremia in several aspects ([Table 3](#T3){ref-type="table"}).

###### Comparison of community-acquired vs. nosocomial *Aeromonas* bacteremia and ceftriaxone-resistant vs. ceftriaxone-susceptible *Aeromonas* bacteremia
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                                                                           Community-acquired (n = 242)   Nosocomial (n = 94)   *P*-value   Ceftriaxone-susceptible (n = 284)   Ceftriaxone-resistant (n = 52)   *P*-value
  ------------------------------------------------------------------------ ------------------------------ --------------------- ----------- ----------------------------------- -------------------------------- -----------
  Age, years                                                               58.48                          52.00                 0.013       59.12                               56.22                            0.578
  Male, n (%)                                                              174 (71.9%)                    62 (65.6%)            0.846       204                                 32                               0.338
  Pitt bacteremia score                                                    1.85                           1.36                  0.333       1.54                                2.69                             0.008
  Mortality                                                                32 (13.2%)                     18 (19.1%)            0.171       38 (13.4%)                          12 (23.1%)                       0.088
  Site of infection, n (%)                                                                                                                                                                                       
   Hepatobiliary infection                                                 140 (57.9%)                    30 (31.9%)            0.003       136 (47.9%)                         34 (65.4%)                       0.003
   Spontaneous bacterial peritonitis                                       54 (22.3%)                     8 (8.5%)              0.003       62 (21.8%)                          0 (0%)                           \< 0.001
   Pneumonia                                                               6 (2.5%)                       14 (14.9%)            0.002       12 (42.3%)                          8 (15.4%)                        0.006
  Underlying diseases, n (%)                                                                                                                                                                                     
   Hepatic cirrhosis                                                       108 (44.6%)                    24 (25.5%)            0.001       122 (43.0%)                         10 (19.2%)                       0.001
   Solid organ malignancy                                                  105 (43.4%)                    37 (39.4%)            0.056       119 (41.9%)                         23 (44.2%)                       0.008
  Devices, n (%)                                                                                                                                                                                                 
   Central line insertion                                                  42 (17.4%)                     38 (40.4%)            \< 0.001    58 (20.4%)                          22 (42.3%)                       0.001
   Urinary catheter insertion                                              50 (20.7%)                     32 (34.0%)            0.010       58 (20.4%)                          24 (46.2%)                       \< 0.001
  Laboratory data (mean)                                                                                                                                                                                         
   Hemoglobin (g/dL)                                                       10.58                          9.42                  \< 0.001    10.25                               10.33                            0.506
   Prothrombin time (INR)                                                  2.06                           2.96                  0.004       1.88                                1.97                             0.021
   Alanine transaminase (ALT) (U/L)                                        99.6                           111.1                 0.088       133.6                               257.4                            \< 0.001
   Bilirubin (mg/dL)                                                       7.96                           10.67                 0.008       5.97                                6.74                             0.093
   Glucose (mg/dL)                                                         166.8                          230.4                 0.001       160.98                              182.69                           0.207
  Clinical manifestations, n (%)                                                                                                                                                                                 
   Shock                                                                   64 (26.4%)                     22 (23.4%)            0.566       68 (23.9%)                          18 (34.6%)                       0.120
   Cardiopulmonary resuscitation                                           12 (5.0%)                      2 (2.1%)              0.244       6 (2.1%)                            8 (15.4%)                        \< 0.001
   Mental change                                                           45(18.6%)                      15(16.0%)             0.045       48 (16.9%)                          12 (23.1%)                       0.445
    Aeromonas isolates                                                                                                          0.003                                                                            0.004
  Usage of Antimicrobial agent                                                                                                                                                                                   
   Initial inappropriate antimicrobial agent                               72 (29.8%)                     68 (72.3%)            0.004       44 (15.5%)                          26 (50.0%)                       \< 0.001
   Initiation of antimicrobial agent within 6 h of symptom manifestation   68 (28.1%)                     60 (63.8%)            \<0.001     34 (12.0%)                          30 (57.7%)                       \< 0.001
  Antimicrobial resistance                                                                                                                                                                                       
   Ampicillin/Sulbactam                                                    162 (66.9%)                    82 (87.2%)            0.018       202 (71.1%)                         42 (80.7%)                       0.351
   Piperacillin                                                            46 (19.0%)                     42 (44.7%)            \< 0.001    56 (19.7%)                          32 (61.5%)                       \< 0.001
   Piperacillin/Tazobactam                                                 28 (11.6%)                     24 (25.5%)            0.001       24 (8.5%)                           28 (53.8%)                       \< 0.001
   Ceftriaxone                                                             28 (11.6%)                     24 (25.5%)            0.001       0 (0%)                              52 (100%)                        
   Ceftazidime                                                             6 (2.5%)                       18 (19.1%)            \<0.001     2 (0.7%)                            22 (42.3%)                       \< 0.001
   Imipenem                                                                21 (5.8%)                      12 (12.8%)            0.009       26 (9.2%)                           7 (13.5%)                        0.377
   Gentamycin                                                              10 (5.6%)                      14 (14.9%)            0.001       18 (6.3%)                           6 (11.5%)                        0.401
   Ciprofloxacin                                                           24 (9.9%)                      10 (10.6%)            0.844       18 (6.3%)                           16 (30.8%)                       0.001

A total of 242 patients had been diagnosed with community-acquired *Aeromonas* bacteremia. Univariate analysis revealed statistically significant differences in age, ICU admission, hospital stay, site of infection, underlying diseases (liver cirrhosis, leukemia), concurrent chemotherapy, presence of a central line catheter, blood laboratory results (hemoglobin, prothrombin time \[PT\], activated partial thromboplastin time \[aPTT\], aspartate transaminase \[AST\], bilirubin, and glucose), presence of cardiopulmonary resuscitation, species differences, proportion of initial discordant antimicrobial agent use, initiation of appropriate antimicrobial agent after 6 h, and antimicrobial resistance between community- and hospital-acquired *Aeromonas* bacteremia. Hepatobiliary infections (*P* = 0.003) and spontaneous bacterial peritonitis (*P* = 0.038) were more common in community-acquired bacteremia; primary bacteremia (*P* = 0.003), pneumonia (*P* = 0.002), and catheter-related infection (*P* = 0.000) were more common in hospital-acquired bacteremia. Liver cirrhosis was the common underlying condition in community-acquired bacteremia (*P* = 0.023), whereas leukemia (*P* = 0.001) and concurrent chemotherapy (*P* = 0.002) were the common underlying conditions in hospital-acquired bacteremia. The laboratory findings were more abnormal in cases of hospital-acquired bacteremia (*P* = 0.009 to 0.045).

5. Antimicrobial therapy {#sec5}
------------------------

*Empirical therapy*. Twelve patients died of septic shock with multi-organ failure before appropriate antimicrobial agent treatment could be started. A total of 140 cases were started with inappropriate antibiotics; half of the patients (166) were administered combination therapy, while 56 were placed on aminoglycoside combination therapy. The most common initially administered antimicrobial agents were ceftriaxone and metronidazole (100 cases). Ceftriaxone was the single most common agent in the empirical therapy for *Aeromonas* bacteremia (61.1%).

*Definitive therapy*. The therapeutic efficacy of the definitive therapy was evaluated in 310 patients. There were no statistically significant differences in mortality between monotherapy and combination therapy (*P* \>0.050).

*Time to the start of antimicrobial agents*. There was a statistically significant difference in mortality between the 6 h prior to and after the initiation of appropriate antimicrobial agents (*P* = 0.049).

6. Ceftriaxone resistance {#sec6}
-------------------------

Among 336 cases of *Aeromonas* monomicrobial bacteremia, 284 (84.5%) had been caused by ceftriaxone-susceptible (CS) *Aeromonas* bacteremia and 52 (15.5%) by ceftriaxone-resistant (CR) *Aeromonas* bacteremia ([Table 3](#T3){ref-type="table"}). The CS and CR *Aeromonas* bacteremia groups had similar demographic characteristics. There was a higher rate of mortality in the CR *Aeromonas* bacteremia group, but this difference was not statistically significant (*P* = 0.088; [Table 3](#T3){ref-type="table"}). The CR *Aeromonas* bacteremia group showed a tendency to disease acquired in a hospital setting (*P* = 0.002).

7. Outcome analysis for non-survivors {#sec7}
-------------------------------------

The overall mortality among the 336 patients was 15.0% (50 cases). Death occurred at a median of 10 days post-admission. Twelve patients died within 72 h of their arrival at the hospital. All of the non-survivors had experienced shock. Furthermore, according to univariate analysis, these cases manifested a higher rate of resistance to antimicrobial agents. A number of risk factors for *Aeromonas* bacteremia-related mortality were found in the multivariate analysis: metastatic cancer, shock, high Pitt bacteremia score, high Charlson's weighted comorbidity index, high prothrombin time, high serum creatinine level, and initiation of appropriate antimicrobial agents 6 h after manifestation of symptoms (*P \<*0.05 for all variables; [Table 4](#T4){ref-type="table"}). The predicted *Aeromonas* monomicrobial bacteremia mortality rate was found to be closely related to the known Pitt bacteremia score.

###### Risk factors for fatality of *Aeromonas* bacteremia
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                                                                               Odd ratio (95% Confidence interval)   *P*-value
  ---------------------------------------------------------------------------- ------------------------------------- -----------
  Univariate analysis                                                                                                
   Underlying disease                                                                                                
    Chronic renal failure                                                      14.737                                \< 0.001
    Metastatic cancer                                                          7.154                                 0.007
    Diabetes mellitus                                                          5.603                                 0.018
    Cerebrovascular attack                                                     4.367                                 0.037
    Quadriparesis                                                              4.367                                 0.037
    Myocardial infarct                                                         4.367                                 0.037
   Pitt bacteremia score                                                       50.871                                \< 0.001
   Charlson weighted comorbidity index                                         5.473                                 0.019
   Primary site of infections                                                                                        
    Hepatobiliary origin                                                       8.064                                 0.005
    Skin and soft-tissue infection                                             4.739                                 0.034
   Clinical manifestations                                                                                           
    Shock                                                                      35.861                                \< 0.001
    Altered mental status                                                      56.179                                \< 0.001
    Hypothermia                                                                24.029                                \< 0.001
    Cardiopulmonary resuscitation                                              25.005                                \< 0.001
    Acute renal failure                                                        23.520                                \< 0.001
   Devices                                                                                                           
    Central line                                                               17.546                                \< 0.001
    Urinary catheterization                                                    29.127                                \< 0.001
    Ventilator                                                                 4.850                                 0.028
   Laboratory data                                                                                                   
    Hemoglobin (g/dL)                                                          -3.177                                0.003
    Prothrombin time (INR)                                                     16.159                                0.000
    activated partial thromboplastin time (aPTT)                               4.395                                 0.036
    Albumin (g/dL)                                                             -2.699                                0.011
    Bilirubin (mg/dL)                                                          11.266                                0.001
    Aspartate transaminase (AST) (U/L)                                         3.382                                 0.001
    Alanine transaminase (ALT) (U/L)                                           3.641                                 \< 0.001
    Blood urea nitrogen (mg/dL)                                                3.329                                 0.011
    Creatinine (mg/dL)                                                         30.617                                \< 0.001
    Glucose (mg/dL)                                                            6.024                                 0.014
    Potassium (mmol/L)                                                         6.121                                 0.013
   Antimicrobial resistance                                                                                          
    Resistance to Tobramycin                                                   4.840                                 0.028
    Resistance to Gentamicin                                                   3.969                                 0.046
    Resistance to Amikacin                                                     4.367                                 0.037
    History of Previous carbapenem use                                         4.786                                 0.029
    Initiation of antimicrobial agent within 6 h after symptom manifestation   0.445                                 0.049
    Initial inappropriate antimicrobial agent                                  13.064                                0.001
    Duration of antimicrobial agents                                           18.292                                \< 0.001
   Others                                                                                                            
    Previous hepatobiliary operation                                           7.147                                 0.028
    *Aeromonas hydrophila*                                                     8.064                                 0.005
  Multivariate analysis                                                                                              
   Metastatic cancer                                                           7.166 (5.354-9.004)                   0.003
   Shock                                                                       3.909 (3.214-5.417)                   0.048
   Pitt bacteremia score                                                       6.486 (1.980-21.249)                  0.002
   Charlson weighted comorbidity index                                         1.536 (1.022-2.309)                   0.039
   Prothrombin time (INR)                                                      2.446 (1.270-4.709)                   0.007
   Creatinine (mg/dL)                                                          4.093 (1.165-14.376)                  0.028
   Initiation of antimicrobial agent within 6 h after manifesting symptoms     0.527 (0.112-0.912)                   0.043

Predicted mortality rate (%) = (Pitt bacteremia score × 0.084 + 0.005) × 100

Discussion
==========

Our study included a large number of cases of monomicrobial *Aeromonas* bacteremia, with full laboratory and medical records; these were amenable to analysis and could provide useful information for better clinical practice.

The three major clinical categories of *Aeromonas* infection are hepatobiliary tract infection, peritonitis, and primary bacteremia. These have been identified in more than 80% of reported *Aeromonas* infections. An earlier study found that the most common underlying conditions associated with *Aeromonas* septicemia were malignancy (21--50%) and hepatobiliary diseases (15--54%) \[[@B2][@B4][@B7][@B12][@B13][@B14]\], although healthy patients were also shown to be susceptible to *Aeromonas* infection. Likewise, underlying illness with malignancy, hepatobiliary diseases, and diabetes mellitus were frequently encountered in *Aeromonas* bacteremia in this study. As many as 25.6% of patients in the present study had diabetes mellitus, which was a significantly higher rate than that previously reported 11% \[[@B5]\]. Our data suggested that individuals presenting with *Aeromonas* bacteremia should be evaluated for the possibility of underlying malignancy, hepatobiliary diseases, or diabetes mellitus.

Previous reports have shown that patients with *Aeromonas* bacteremia could be treated with one of the broad-spectrum β-lactam agents, such as third-generation cephalosporins, aztreonam, and imipenem, or with fluoroquinolone alone \[[@B2][@B5][@B7]\]. However, antimicrobial resistance to extended-spectrum cephalosporins (such as cefotaxime) in clinical *Aeromonas* isolates has been noted \[[@B1][@B2][@B4][@B5][@B6][@B7][@B11][@B12][@B14][@B15][@B16][@B17]\]. Indeed, fluoroquinolone resistance is increasing, as evidenced by the ciprofloxacin-resistance rate of 14% that was previously reported \[[@B2]\]. In the current study, the rates of resistance to ceftriaxone, ciprofloxacin, and imipenem were 15.5, 10.1, and 9.8%, respectively. It has been shown that, for carbapenemase-producing *Aeromonas* strains, the MICs of imipenem were above 8 mg/L \[[@B6]\]. However, the clinical effect of the inducible carbapenemases in clinical *Aeromonas* species has not been clearly delineated as yet \[[@B2][@B6]\]. One case study reported an imipenem-resistant *A. veronii* clinical isolate, recovered from a patient with cholangitis; this case also did not show any clinically significant carbapenem-resistance in *Aeromonas* species \[[@B18][@B19]\]. A history of carbapenem use was associated with mortality in the present univariate analysis. This suggests that previous carbapenem use can induce resistance and thereby lead to a poor clinical outcome.

Based on the resistance rates found in our data, amikacin, gentamicin, ceftazidime, imipenem, and ciprofloxacin are reasonable antimicrobial therapy choices for treatment of *Aeromonas* infections. Ceftriaxone is the usual empirical treatment of choice for patients with hepatobiliary infections. Ceftriaxone was started as the initial treatment in most cases of suspected gastrointestinal or hepatobiliary infection identified in the present study. The high resistance patterns led to 41.7% of patients being treated with inappropriate empirical antimicrobial therapy. Additionally, ceftriaxone-resistant *Aeromonas* bacteremia groups showed severe clinical manifestations and laboratory findings. The only exceptions were the *Aeromonas* isolates from Jeju University Hospital, all of which (n = 20) were susceptible to piperacillin, piperacillin/tazobactam, ceftriaxone, ceftazidime, imipenem, ciprofloxacin, tobramycin, gentamicin, and amikacin. Thus, geographic differences may affect resistance patterns. Recommendations for combination therapy in *Aeromonas* bacteremia have come from studies of a small number of cases with both polymicrobial and monomicrobial bacteremia \[[@B20][@B21]\]. In contrast, in the current study, there was no significant difference in the clinical outcomes of patients definitively treated with either monotherapy or combination therapy. However, we cannot recommend either monotherapy or combination therapy for treatment of *Aeromonas* bacteremia at this point, because the proportion of inappropriate initial therapy was high in our experience. Given the lack of available therapeutic options for *Aeromonas* bacteremia, well-controlled clinical trials of combinations of existing antibiotics are urgently needed.

*A. caviae* is the most frequent pathogen causing *Aeromonas* bacteremia in Japan \[[@B19][@B22]\], whereas *A. hydrophila*, followed by *A. veronii* biovar *sobria*, is the most common *Aeromonas* species causing bacteremia in Taiwan \[[@B23]\]. In our study, *A. hydrophila* was the most common *Aeromonas* species causing bacteremia, followed by *A. caviae*, which is interesting, as Korea is geographically located between China and Japan. Therefore, additional epidemiological studies are required in order to establish the bacteriology of different types of *Aeromonas* infections in different regions. Isolates need to be collected, and the links between genetic factors and geographic areas should be analyzed. This is relevant, as in this study, *A. hydrophila* showed higher antimicrobial resistance and resulted in greater clinical severity than did the other *Aeromonas* spp. (*P* \<0.05).

The mortality rates among patients with *Aeromonas* bacteremia range from 28 to 63% in the literature \[[@B1][@B2][@B4][@B7][@B18][@B24][@B25]\]. However, our study showed a significantly lower mortality rate (14.9%). In our cases, patients with skin and soft-tissue infection had worse clinical outcomes than did those with other secondary bacteremia; this finding was statistically significant only in univariate analysis. Bacterial peritonitis has been associated with an approximate 15% mortality rate, and necrotizing fasciitis with a higher mortality rate of 50% (one death in two patients). In our study, the number of patients with necrotizing fasciitis was 14. We postulated that the lower mortality rate in our study was associated with a low prevalence of soft-tissue infection as well as a relatively low rate of liver cirrhosis \[[@B7]\]. Inappropriate therapy has been regarded as a prognostic factor in patient outcomes \[[@B26]\], and was correlated with mortality in this study.

The main limitation of this study was its retrospective design. As such, specific information on the antibiotic types (cefepime and aztreonam) used was missing from the medical records. Furthermore, our study was conducted at four tertiary hospitals and examined data spanning 14 years. During that time, medical and microbiological environments changed, and thus our results cannot be generalized to all other hospitals.

In conclusion, patients with *Aeromonas* bacteraemia can be treated with carbapenem, ceftazidime, or fluoroquinolone. Although *Aeromonas* species showed a higher resistance rate to ceftriaxone, *Aeromonas* bacteremia was correlated with a relatively low mortality rate compared with previous studies. All of the non-survivors experienced shock. Ceftriaxone-based metronidazole combination treatment might not be recommendable as an initial empirical therapy, in particular due to the high antimicrobial resistance rates to various agents in septic-shock patients. In patients with septic shock, carbapenem-based aminoglycoside combination treatment may also not be considered as an initial empirical therapy, due to the high antimicrobial-resistance rates to various agents present in septic shock. Considering the risk factors for mortality, adequate antibiotics should be given early, especially to patients with shock and impaired renal function. In order to make recommendations for definitive therapy based on available susceptibility results, further studies with larger numbers of cases and supportive experiment, such as DNA sequencing, are warranted.
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